LYMPHANGIOLEIOMYOMATOSIS (LAM)
Clinical trials for LYMPHANGIOLEIOMYOMATOSIS (LAM) explained in plain language.
Never miss a new study
Get alerted when new LYMPHANGIOLEIOMYOMATOSIS (LAM) trials appear
Sign up with your email to follow new studies for LYMPHANGIOLEIOMYOMATOSIS (LAM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a leukemia drug help fight rare lung disease? new trial aims to find out
Disease control Recruiting nowThis study tests the long-term safety of imatinib, a drug already approved for leukemia, in women with lymphangioleiomyomatosis (LAM), a rare cystic lung disease. Twenty women aged 18-64 with LAM will receive either imatinib or a placebo for 6 months. The goal is to see if imatin…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS (LAM)
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
Could tiny blood bubbles reveal secrets of a rare lung disease?
Knowledge-focused Recruiting nowThis study examines tiny particles called extracellular vesicles in the blood of women with a rare lung disease called LAM. Researchers want to see if these particles can help track how the disease affects the lungs. About 80 women with LAM, related conditions, or healthy lungs w…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS (LAM)
Sponsor: University of Milan • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:51 UTC